Detail

Study ID: Lilly I5B-MC-JGDP Pancreatic

Title:

Phase 1b/II study combining Olaratumab with Abraxane and Gemcitabine. Phase 1b will consist of an open-label dose finding study and Phase II will be a double-blinded, randomized study comparing Olaratumab plus Abraxane and Gemcitabine versus placebo plus Abraxane and Gemcitabine.

Location:
Sioux Falls Region
Principal Investigator:
Jonathan Bleeker, MD
Disease:
Pancreas
Stage:
Phase I/II
Status:
Active - Open to Accrual